drugset / Trial / NCT06716281

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

NCT06716281 ↗

Phase 3 Recruiting 398 enrolled Shanghai IxCell Biotechnology Co., LTD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis. To evaluate the safety of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis.

Timeline

Start
2024-01-05
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IxCell hUC-MSC-O Unknown 2 ml Other
Subject IxCell hUC-MSC-O Unknown 5e+07 cells Other

Indications